The relationship between sarcopenia and nesfatin-1 and ghrelin levels in patients with chronic obstructive pulmonary disease

Yıl 2021, , 402 - 407, 15.07.2021

Gülay Daşdemir İlkhan , Selay Arslan , Yücel Arman , Özgür Altun , Hakan Celikhisar , Tufan Tükek

https://doi.org/10.32322/jhsm.896660

Cited By: 1

Öz

Background and Aim: In this study, we aimed to investigate the relationship between the levels of adipocytokines anorexigenic nesfatin-1 and orexigenic ghrelin levels and body mass index (BMI), muscle mass, muscle strength and sarcopenia in patients with chronic obstructive pulmonary disease (COPD).
Material and Method: The patients were divided into two groups according to the severity of COPD. Body mass index (BMI), body fat and muscle measurements were measured with bioelectrical impedance device. A hand-grip strength test was performed with a hand dynamometer to determine muscle strength. We used the mMRC (Modified Medical Research Council Questionnaire) questionnaire to measure the intensity of dyspnea during daily activities. A 6-minute walk test (6MWT) was used to test functional capacity and physical exercise tolerance. COPD Assessment Test (CAT) was performed to determine the health status. Serum nesfatin-1 and ghrelin levels were measured in all patients.
Results: In a total of 90 patients (16 female and 74 male) were included in the study prospectively. There was not any significant difference regarding the Nesfatin-1, ghrelin and Nesfatin-1/ghrelin ratio between mild/moderate or severe COPD patients. Muscle strength was correlated positively with 6MWT, nesfatin-1 and ghrelin levels, but negatively correlated with CAT score and mMRC score. The number of patients in the advanced stage of COPD was higher in the sarcopenia group than in the non-sarcopenia group.
Conclusion: There was a positive correlation between muscle strength and nesfatin-1 and ghrelin levels. However, muscle strength was negatively correlated with mMRC and CAT scores. Approximately 19% of COPD patients had sarcopenia. Serum nesfatin-1 and ghrelin levels were not different between sarcopenic and non-sarcopenic COPD patients.

Anahtar Kelimeler

Chronic obstructive pulmonary disease, ghrelin, nesfatin-1, sarcopenia

Kaynakça

• Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respiratory J 2009; 33: 1165–85.
• Maltais F, Decramer M, Casaburi R, et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014; 189: e15–e62.
• Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia – European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412–23.
• Bauer J, Morley JE, Schols AMWJ, et al. Sarcopenia: a time for action. An SCWD Position Paper. J Cachexia Sarcopenia Muscle 2019; 10: 956-61.
• Dziegala M, Josiak K, Kasztura M, et al. Iron deficiency as energetic insult to skeletal muscle in chronic diseases. J Cachexia Sarcopenia Muscle 2018; 9: 802-15.
• Trajanoska K, Schoufour JD, Darweesh SK, et al. Sarcopenia and its clinical correlates in the general population: The Rotterdam Study. J Bone Miner Res 2018; 33: 1209-18.
• Algül S, Özçelik O. Determination of the effects of acute aerobic exercise on nesfatin-1 levels. Fırat University Med J Health Sci 2016; 30: 5–8.
• Leivo-Korpela S, Lehtimäki L, Hämälainen M, et al. Adipokines NUCB2/nesfatin-1 and visfatin as novel inflammatory factors in chronic obstructive pulmonary disease. Mediators Inflamm 2014; 2014: 232167.
• Gil-Campos M, Aguilera CM, Cañete R, Gil A. Ghrelin: a hormone regulating food intake and energy homeostasis. Br J Nutr 2006; 96: 201-26.
• Disease. GIfCOL. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global initiative for chronic obstructive lung diseases (GOLD). 2014. Available from: http://www.goldcopd.org. Accessed January 1. 
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648-54.
• Cohen RI, Ginsberg N, Tsang D, Wann LC, Ye X, Liu SF. Association of nesfatin-1 and fat mass in cystic fibrosis. Respiration 2013; 86: 312-7.
• Zammit C, Liddicoat H, Moonsie I, Makkeer H. Obesity and respiratory diseases. Int J Gen Med 2010; 3: 335–43. 
• Spelta F, Fratta Pssini AM, Cazzoletti L, Ferrari M. Body weight and mortality in COPD: focus on the obesity paradox. Eat Weight Disord 2018; 23: 15–22.
• Yang L, Zhu Y, Huang JA, Jin J, Zhang X. A low lean-to-fat ratio reduces the risk of acute exacerbation of chronic obstructive pulmonary disease in patients with a normal or low body mass index. Med Sci Monit 2019; 25: 5229–36.
• Yamamoto C, Yoneda T, Yoshikawa M, et al. The relationship between a decrease in fat mass and serum levels of TNF-alpha in patients with chronic obstructive pulmonary disease. Nihon Kyobu Shikkan Gakkai Zasshi 1997; 35: 1191-5.
• Poberezhets V, Mostovoy Y, Demchuk H. Exacerbation of chronic obstructive pulmonary diseases as a risk factor of the skeletal muscle dysfunction. Lung India 2019; 36: 188-92.
• Graumam RQ, Pinheiro MM, Nery LE, Castro CHM. Increased rate of osteoporosis, low lean mass, and fragility fractures in COPD patients: association with disease severity. Osteoporos Int 2018; 29: 1457-68.
• Park CH, Yi Y, Do JG, Lee YT, Yoon KJ. Relationship between skeletal muscle mass and lung function in Korean adults without clinically apparent lung disease. Medicine (Baltimore) 2018; 97: e12281.
• Kyomoto Y, Asai K, Yamada K, et al. Handgrip strength measurement in patients with chronic obstructive pulmonary disease: Possible predictor of exercise capacity. Respir Investig 2019; 57: 499-505.
• Itoh T, Nagaya N, Yoshikawa M, et al. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 879-82.
• Deveci Y, Deveci F, Ilhan N, Karaca I, Turgut T, Muz MH. Serum ghrelin, IL-6 and TNF-α levels in patients with chronic obstructive pulmonary disease. Tuberk Toraks 2010; 58: 162–7. Turkish.
• Kamiide Y, Inomata N, Furuya M, Yada T. Ghrelin ameliorates catabolic conditions and respiratory dysfunction in a chronic obstructive pulmonary disease model of chronic cigarette smoke-exposed rats. Eur J Pharmacol 2015; 755: 88-94.
• Kim SH, Shin MJ, Shin YB, Kim KU. Sarcopenia Associated with Chronic Obstructive Pulmonary Disease. J Bone Meta 2019; 26: 65-74.
• Jones SE, Maddocks M, Kon SS, et al. Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax 2015; 70: 213-8.
• Kwan HY, Maddocks M, Nolan CM, et al. The prognostic significance of weight loss in chronic obstructive pulmonary disease-related cachexia: a prospective cohort study. J Cachexia Sarcopenia Muscle 2019; 10: 1330-8.
• Pothirat C, Chaiwong W, Phetsuk N, et al. The Relationship between Body Composition and Clinical Parameters in Chronic Obstructive Pulmonary Disease.J Med Assoc Thai 2016; 99: 386-93.
• Gologanu D, Ionita D, Gartonea T, Stanescu C, Bogdan MA. Body composition in patients with chronic obstructive pulmonary disease. Maedica (Buchar) 2014; 9: 25-32.
• Serra-Prat M, Papiol M, Monteis R, Palomera E, Cabré M. Relationship between Plasma Ghrelin Levels and Sarcopenia in Elderly Subjects: A Cross-Sectional Study. J Nutr Health Aging 2015; 19: 669-72.
• Zhang X, Yang T, Wang J, et al. Elevated circulating ghrelin in patients with COPD: A meta-analysis.Chron Respir Dis 2018; 15: 365-73.